2021
Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.
Spees L, Wheeler S, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M. Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2021, 39: 87-87. DOI: 10.1200/jco.2020.39.28_suppl.87.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaPatient-level factorsProvider-level factorsRenal cell carcinomaIndex dateRace/ethnicityInitial diagnosisCell carcinomaRisk ratioState cancer registry dataNumber of comorbiditiesMore comorbid conditionsPatient-level predictorsCancer registry dataProportion of daysProvider-level variablesPrescription drug filesMedian PDCMRCC diagnosisMRCC patientsPatient characteristicsPharmacy claimsComorbid conditionsMetastatic diagnosisMedical oncologyAdoption of consolidative durvalumab among patients with locally advanced non-small cell lung cancer.
Jairam V, Pasha S, Soulos P, Goldberg S, Yu J, Decker R, Gross C, Park H. Adoption of consolidative durvalumab among patients with locally advanced non-small cell lung cancer. Journal Of Clinical Oncology 2021, 39: e20550-e20550. DOI: 10.1200/jco.2021.39.15_suppl.e20550.Peer-Reviewed Original ResearchNon-small cell lung cancerCell lung cancerTumor characteristicsLung cancerFDA approvalConsolidative durvalumabPatient characteristicsUnresectable stage III non-small cell lung cancerStage III non-small cell lung cancerAdvanced non-small cell lung cancerFirst-line platinum-doublet chemotherapyStudy periodFlatiron Health databasePlatinum-doublet chemotherapyGuideline-concordant carePD-L1 statusMultivariable logistic regressionCochran-Armitage testDe-identified databaseChi-square testDefinitive chemoradiationDoublet chemotherapyEligible patientsPACIFIC trialSurgery details
2020
The adoption of immune checkpoint inhibitors and patterns of care at the end of life.
Riaz F, Gan G, Li F, Davidoff A, Adelson K, Presley C, Adamson B, Shaw P, Parikh R, Mamtani R, Gross C. The adoption of immune checkpoint inhibitors and patterns of care at the end of life. Journal Of Clinical Oncology 2020, 38: 12027-12027. DOI: 10.1200/jco.2020.38.15_suppl.12027.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune checkpoint inhibitorsUse of chemotherapyMSS colon cancerEnd of lifeSystemic therapySystemic cancer therapyColon cancerFDA approvalCheckpoint inhibitorsBiologic therapyPatient characteristicsUse of ICIsCell lung cancerPatterns of careCare of patientsMicrosatellite stable colon cancerPearson's chi-square testPatient-level dataCancer therapyDays of lifeDe-identified databaseSignificant increaseChi-square testAggressive therapy
2018
Defining, Measuring and Preventing the Diagnosis of Cancer as an Emergency: A Critical Review of Current Evidence
Zhou Y, Abel G, Hamilton W, Pritchard-Jones K, Gross C, Walter F, Renzi C, Johnson S, McPhail S, Elliss-Brookes L, Lyratzopoulos G. Defining, Measuring and Preventing the Diagnosis of Cancer as an Emergency: A Critical Review of Current Evidence. Journal Of Global Oncology 2018, 4: 48s-48s. DOI: 10.1200/jgo.18.45300.Peer-Reviewed Original ResearchEmergency presentationDiagnosis of cancerProportion of patientsPatient-reported outcomesPopulation-based studyHealth care useHealth care factorsHealth care interventionsPatient characteristicsPatient's symptomsLung cancerCurrent evidencePatientsDifferent tumorsCancerCancer typesLimited evidenceDiagnosisCancer diagnosisPublic healthPresentationSymptomsSuch presentationsConsistent inequalitiesRelevant evidenceAdherence to Guidelines for Breast Surveillance in Breast Cancer Survivors.
Ruddy KJ, Sangaralingham L, Freedman RA, Mougalian S, Neuman H, Greenberg C, Jemal A, Duma N, Haddad TC, Lemaine V, Ghosh K, Hieken TJ, Hunt K, Vachon C, Gross C, Shah ND. Adherence to Guidelines for Breast Surveillance in Breast Cancer Survivors. Journal Of The National Comprehensive Cancer Network 2018, 16: 526-534. PMID: 29752327, DOI: 10.6004/jnccn.2018.7001.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsCancer survivorsBreast cancerDecreased likelihoodDefinitive breast cancer surgeryLikelihood of mammographySurvivorship care guidelinesCurative-intent treatmentProportion of patientsNonmetastatic breast cancerResidual breast tissueBreast cancer surgeryAdministrative claims dataBreast imagingBreast cancer treatmentMedicare Advantage beneficiariesBreast surveillanceInsured cohortPatient characteristicsAnnual mammographyCancer surgeryCare guidelinesBreast surgeryHealthcare useBlack race
2017
Risk factors for hospitalizations (HOS) among older adults with gastrointestinal (GI) cancers receiving chemotherapy.
Li D, Sun C, Levi A, Klepin H, Elias R, Mohile S, Tew W, Lim D, Chung V, Chao J, Owusu C, Muss H, Lichtman S, Gross C, Chapman A, Gajra A, Cohen H, Katheria V, Hurria A. Risk factors for hospitalizations (HOS) among older adults with gastrointestinal (GI) cancers receiving chemotherapy. Journal Of Clinical Oncology 2017, 35: e21523-e21523. DOI: 10.1200/jco.2017.35.15_suppl.e21523.Peer-Reviewed Original ResearchGI cancersRisk factorsCardiac comorbiditiesOlder adultsGeriatric assessmentOdds ratioLow serum albuminStage IV diseaseIncidence of hospitalizationRisk of hospitalizationAdults age 65Days post treatmentChemotherapy typePatient agePatient characteristicsProspective studyFemale sexGastrointestinal cancerChemotherapy treatmentUnivariate analysisLaboratory valuesHospitalizationChemotherapyMultivariate analysisPatientsDisparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer.
Presley C, Soulos P, Chiang A, Longtine J, Adelson K, Herbst R, Nussbaum N, Sorg R, Abernethy A, Agarwala V, Gross C. Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer. Journal Of Clinical Oncology 2017, 35: 6563-6563. DOI: 10.1200/jco.2017.35.15_suppl.6563.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerNGS testingLung cancerBiomarker testingOncology practiceNext-generation sequencingNon-squamous non-small cell lung cancerPopulation-based community cohortReal-world clinical practiceMulti-gene panel testingInsurance-related disparitiesAdvanced lung cancerFirst-line treatmentHistory of smokingRetrospective observational studyElectronic health record dataWorld clinical practiceClustering of patientsHealth record dataYounger patientsMedian agePatient characteristicsWhite patientsThe Impact of Social Contagion on Physician Adoption of Advanced Imaging Tests in Breast Cancer
Pollack CE, Soulos PR, Herrin J, Xu X, Christakis NA, Forman HP, Yu JB, Killelea BK, Wang SY, Gross CP. The Impact of Social Contagion on Physician Adoption of Advanced Imaging Tests in Breast Cancer. Journal Of The National Cancer Institute 2017, 109: djw330. PMID: 28376191, PMCID: PMC6059114, DOI: 10.1093/jnci/djw330.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingBaseline usePositron emission tomography scanEnd Results-MedicareEmission tomography scanBreast cancer practiceImaging modalitiesAdvanced imaging testsHierarchical logistic regression modelsLogistic regression modelsPatient characteristicsUnproven benefitCancer practiceMRI/PETTomography scanBreast cancerMRI useImaging testsClinical practicePET useResonance imagingPET imagingPhysician peersPhysician adoptionBaseline period
2012
The influence of physician densities and patient characteristics on the decision to treat prostate cancer patients with varying clinical benefit.
Yu J, Aneja S, Makarov D, Roberts K, Gross C. The influence of physician densities and patient characteristics on the decision to treat prostate cancer patients with varying clinical benefit. Journal Of Clinical Oncology 2012, 30: 19-19. DOI: 10.1200/jco.2012.30.5_suppl.19.Peer-Reviewed Original ResearchHealth system factorsHealth service areasCurative therapyUrologist densityClinical benefitProstate cancerRadiation oncologistsPhysician densitySystem factorsRadiation oncologist densityEnd Results (SEER) databaseLower likelihoodReceipt of treatmentMarital statusProstate cancer patientsHigher likelihoodLogistic regression modelsArea Resource FilePatient characteristicsPatient factorsInitial treatmentResults databasePatient populationCancer patientsProper therapy
2011
The Influence of Physician Densities and Patient Characteristics on the Decision to Treat Prostate Cancer Patients with Varying Clinical Benefit
Aneja S, Makarov D, Gross C, Roberts K, Yu J. The Influence of Physician Densities and Patient Characteristics on the Decision to Treat Prostate Cancer Patients with Varying Clinical Benefit. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s553. DOI: 10.1016/j.ijrobp.2011.06.871.Peer-Reviewed Original ResearchProstate cancer patientsPatient characteristicsClinical benefitCancer patientsPhysician densityPatients